

AMENDMENTS TO THE CLAIMS

1. (Currently amended) An isolated nucleic acid molecule comprising the eDNA represented as a nucleotide sequence of SEQ ID NO:2, which codes for Saxatilin, a protein derived from venom of Agkistrodon saxatilis emelianov.
2. (Currently amended) An isolated polypeptide comprising the Saxatilin represented as an amino acid sequence of SEQ ID NO:1 which is derived from the eDNA of claim 1.
3. (Currently amended) A process for preparing Saxatilin a polypeptide comprising the amino acid sequence of SEQ ID NO:1 ~~which comprises~~ comprising the steps of:
 - (i) gel filtration of venom collected from Agkistrodon saxatilis emelianov to obtain an active fraction having an inhibitory effect on platelet aggregation; and,
 - (ii) applying the active fraction to high performance liquid chromatography to purify Saxatilin a polypeptide comprising the amino acid sequence of SEQ ID NO:1.
4. (Currently amended) An expression vector ~~pPSAX containing~~ comprising the eDNA nucleic acid molecule of claim 1.
5. (Currently amended) A biologically pure culture of Pichia pastoris Y/pPSAX (KCCM-10201) which is obtained by transforming the expression vector ~~pPSAX~~ of claim 4 into Pichia pastoris GS115.
6. (Currently amended) A process for preparing a recombinant Saxatilin polypeptide comprising the amino acid sequence of SEQ ID NO:1 which comprises a step of culturing a microorganism transformed with an expression vector containing the eDNA nucleic acid molecule

of claim 1 to obtain a recombinant Saxatilin polypeptide comprising the amino acid sequence of SEQ ID NO:1.

7. (Currently amended) The process for preparing the recombinant Saxatilin polypeptide of claim 6, wherein the expression vector is pPSAX.

8. (Currently amended) The process for preparing the recombinant Saxatilin polypeptide of claim 6, wherein the transformed microorganism is *Pichia pastoris* Y/pPSAX (KCCM-10201).

9. (Currently amended) The process for preparing the recombinant Saxatilin polypeptide of claim 8, wherein the transformed microorganism is cultured under [[a]] conditions of pH 5.5 to 6.5, 25°C to 35°C for 12 to 24 hours, harvested by centrifugation and cultured again [[on]] in a medium containing 0.5% to 1.5% (v/v) methanol under [[a]] conditions of pH 5.5 to 6.5, 25°C to 35°C for 72 to 120 hours.

10. (Currently amended) The process for preparing the recombinant Saxatilin polypeptide of claim 8, wherein [[the]] supernatant from a culture containing the transformed microorganism is collected and subjected to a hydrophobic column and high performance liquid chromatography to purify Saxatilin.

11. (Currently amended) A pharmaceutical composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO:1 Anti-platelet agent comprising an active ingredient of Saxatilin and a pharmaceutically acceptable carrier.

12. (Currently amended) The pharmaceutical composition of claim 11, wherein said composition is an [[Anti]] anti-tumor agent comprising an active ingredient of Saxatilin and pharmaceutically acceptable carrier.

13. (New) The pharmaceutical composition of claim 11, wherein said composition is an anti-platelet aggregation agent.